Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating infliximab for moderate-to-severe refractory intestinal Behcet's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behcet Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Behcet Disease | Phase 3 | Status: COMPLETED